Enhancement in vivo of the antiinflammatory and antitumor activities of type I interferon by association with the synthetic immunomodulator murabutide

Journal of Interferon and Cytokine Research

Volumn 16, Issue 4, 1996, Pages 297-306

  Bahr, George M ^a  

^a Vacsyn SA   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CONCANAVALIN A; GAMMA INTERFERON; IMMUNOMODULATING AGENT; INTERFERON; MESSENGER RNA; MURABUTIDE; MURAMYL PEPTIDE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 6;

ACUTE HEPATITIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDICATION; DRUG POTENTIATION; FEMALE; IMMUNOMODULATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER INJURY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SARCOMA;

EID: 0029878037     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.1996.16.297     Document Type: Article

References (5)

1. GUTTERMAN, J.U. (1994). Cytokine therapeutics: lessons from Interferon α. Proc. Natl. Acad. Sci. USA 91, 1198-1205.
2. BARON, S., TYRING, S.K., FLEISCHMANN, W.R., JR., COPPENHAVER, D.H., NIESEL, D.W., KLIMPEL, G.R., STANTON, G J., and HUGHES, T.K. (1991). The interferons. Mechanism of action and clinical applications. JAMA 266, 1375-1383.
3. HEREMANS, H., and BILLIAU, A. (1989). The potential role of interferons and interferon antagonists in inflammatory disease. Drugs 38, 957-972.
4. TILG, H., MIER, J.W., VOGEL, W., AULITZKY, W.E., WEIDERMAN, C.J., VANNIER, E., HUBER, C., and DINAR-ELLO, C.A. (1993). Induction of circulating IL-1 receptor antagonist by IFN treatment. J. Immunol. 150, 4687-4692.
5. BAHR, G.M., DARCISSAC, E., BEVEC, D., DUKOR, P., and CHEDID, L. (1995). Immunopharmacological activities and clinical development of muramyl peptides with particular emphasis on murabutide. Int. J. Immunopharmacol. 17, 117-131.